Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
ANVS Stock Chart & Stats
$3.04
-$0.04(-0.79%)
At close: 4:00 PM EST
$3.04
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.11 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)474.52K
Market Cap
$76.86M
Enterprise Value$44.52M
Total Cash (Recent Filing)$15.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.24
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding26,502,890
10 Day Avg. Volume480,302
30 Day Avg. Volume474,519
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.58
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.68
Forecast
1Y Price Target
$12.50Price Target Upside311.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceReductions in tau species and multiple neuroinflammation markers, together with lower neurofilament light chain, suggest buntanetap may be impacting underlying neurodegeneration and support potential disease-modifying activity.
Regulatory EngagementA scheduled Type C meeting with the FDA to discuss development for Parkinson's disease dementia signals active regulatory dialogue that could clarify the approval pathway and de-risk development strategy.
Safety And Commercial ProfileOral dosing and a favorable safety profile observed so far improve patient convenience and reduce clinical development risk, enhancing the drug's commercial appeal if approved.
Bears Say
Cash Runway Vs. Development TimelineCash runway through the third quarter of 2026 may force financing decisions before receipt of pivotal Phase 3 readouts, increasing the risk of dilution or constrained program execution.
Clinical Outcome DependenceCompany valuation appears highly dependent on positive Phase 3 results, so any disappointing clinical data could lead to marked downward pressure on the stock.
Financing RiskOngoing need for additional financing creates uncertainty and could pressure the share price if capital raises are required before clinical milestones are achieved.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.11 and its highest was $5.50 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $76.86M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is May 19, 2026 which is in 109 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Nov 12, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.007.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 26,502,890 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went up 15.166%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (311.18% Upside)
$12.50 (311.18% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.44%
12-Months-Change
Fundamentals
Return on Equity
-246.14%
Trailing 12-Months
Asset Growth
19.69%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(311.18% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
15.22% Insiders
3.11% Mutual Funds
0.24% Other Institutional Investors
78.96% Public Companies and
Individual Investors